(Q54725612)

3 June 2018

title

Early discontinuation of tamoxifen: a lesson for oncologists. (English)

1 reference

3 June 2018

1 reference

Thomas I Barron

1

1 reference

3 June 2018

Róisín Connolly

2

1 reference

3 June 2018

Kathleen Bennett

3

1 reference

3 June 2018

John Feely

4

1 reference

3 June 2018

M John Kennedy

5

1 reference

3 June 2018

language of work or name

English

0 references

publication date

1 March 2007

1 reference

3 June 2018

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

3 June 2018

volume

109

1 reference

3 June 2018

issue

5

1 reference

3 June 2018

page(s)

832-839

1 reference

3 June 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Methods for evaluation of medication adherence and persistence using automated databases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adherence to tamoxifen over the five-year course

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Long-term persistence with antihypertensive drugs in new patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adherence beliefs among breast cancer patients taking tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Intentional and non-intentional non-adherence to medication amongst breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Predictors of medication adherence in the elderly.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adjustment to breast cancer: age-related differences in coping and emotional distress.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

The psychosocial impact of cancer on the elderly: a comparison with younger patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Predicting compliance in a breast cancer prevention trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Oncologists' views of cancer patient noncompliance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Patient noncompliance with self-administered chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Effect of depression on diagnosis, treatment, and survival of older women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Depression as a Prognostic Factor for Breast Cancer Mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Influence of psychological response on survival in breast cancer: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22485

7 January 2021

Identifiers

DOI

10.1002/CNCR.22485

1 reference

3 June 2018

1 reference

3 June 2018